NABRIVA THERAPEUTICS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0001 USD | 0.00% |
|
0.00% | +9,900.00% |
| 2023 | Nabriva Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 | CI |
| 2023 | Nabriva Therapeutics plc(OTCPK:NBRV.F) dropped from NASDAQ Composite Index | CI |
Valuation
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 219.4 | 97.79 | 124.8 | 51.01 | 33.97 | 5.791 |
| Enterprise Value (EV) 1 | 132.8 | 19.28 | 74.82 | 17.53 | -5.676 | -1.402 |
| P/E ratio | -2.4 x | -0.65 x | -1.18 x | -0.45 x | -0.53 x | -0.09 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 41.3 x | 10.1 x | 13.2 x | 10.1 x | 1.18 x | 0.16 x |
| EV / Revenue | 25 x | 2 x | 7.89 x | 3.49 x | -0.2 x | -0.04 x |
| EV / EBITDA | -1.81 x | -0.24 x | -0.95 x | -0.27 x | 0.12 x | 0.03 x |
| EV / FCF | -3.02 x | -0.47 x | -1.8 x | -0.37 x | 0.14 x | 0.09 x |
| FCF Yield | -33.1% | -212% | -55.5% | -272% | 734% | 1,073% |
| Price to Book | 2.67 x | 1.43 x | 3.02 x | 1.54 x | 0.64 x | 1.84 x |
| Nbr of stocks (in thousands) | 147 | 268 | 378 | 843 | 2,269 | 3,064 |
| Reference price 2 | 1,495 | 365.0 | 330.0 | 60.50 | 14.97 | 1.890 |
| Announcement Date | 3/16/18 | 3/12/19 | 3/12/20 | 3/11/21 | 3/29/22 | 4/17/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales 1 | 5.319 | 9.656 | 9.481 | 5.027 | 28.9 | 36.94 |
| EBITDA 1 | -73.34 | -81.82 | -79.09 | -65.71 | -48.17 | -55.27 |
| EBIT 1 | -73.77 | -82.33 | -79.49 | -66.13 | -48.53 | -55.49 |
| Operating Margin | -1,386.88% | -852.6% | -838.4% | -1,315.42% | -167.95% | -150.24% |
| Earnings before Tax (EBT) 1 | -73 | -114.7 | -82.66 | -69.34 | -48.96 | -55.62 |
| Net income 1 | -74.36 | -114.8 | -82.76 | -69.48 | -49.45 | -57.18 |
| Net margin | -1,397.93% | -1,188.69% | -872.95% | -1,382.22% | -171.14% | -154.83% |
| EPS 2 | -623.1 | -564.9 | -278.9 | -135.2 | -28.52 | -21.32 |
| Free Cash Flow 1 | -43.98 | -40.88 | -41.53 | -47.68 | -41.65 | -15.05 |
| FCF margin | -826.86% | -423.32% | -437.99% | -948.5% | -144.13% | -40.74% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/16/18 | 3/12/19 | 3/12/20 | 3/11/21 | 3/29/22 | 4/17/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q1 | 2021 Q2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 2.529 | 8.243 | 8.862 | 9.261 | 8.02 | 9.191 | 9.153 |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | -13.45 | -11.38 | -10.81 | -12.88 | -11.56 | -10.4 | -11.2 |
| Operating Margin | -531.75% | -138.08% | -122.03% | -139.12% | -144.11% | -113.14% | -122.39% |
| Earnings before Tax (EBT) 1 | -13.79 | -11.15 | -10.9 | -13.12 | -11.46 | -10.69 | -10.99 |
| Net income 1 | -13.98 | -11.75 | -10.65 | -13.06 | -11.82 | -11.07 | -11.51 |
| Net margin | -552.83% | -142.59% | -120.2% | -141.05% | -147.37% | -120.49% | -125.79% |
| EPS 2 | -13.25 | -7.250 | -5.250 | -6.000 | -5.000 | -4.500 | -4.210 |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 5/6/21 | 8/5/21 | 11/9/21 | 3/29/22 | 5/5/22 | 8/3/22 | 11/10/22 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 86.6 | 78.5 | 50 | 33.5 | 39.6 | 7.19 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -44 | -40.9 | -41.5 | -47.7 | -41.6 | -15 |
| ROE (net income / shareholders' equity) | -93.3% | -152% | -151% | -187% | -114% | -202% |
| ROA (Net income/ Total Assets) | -48.8% | -49.9% | -48.6% | -54.2% | -43.5% | -61.6% |
| Assets 1 | 152.4 | 230 | 170.4 | 128.2 | 113.6 | 92.89 |
| Book Value Per Share 2 | 559.0 | 256.0 | 109.0 | 39.30 | 23.50 | 1.030 |
| Cash Flow per Share 2 | 591.0 | 381.0 | 227.0 | 49.10 | 21.00 | 3.880 |
| Capex 1 | 1.17 | 0.23 | 0.06 | 0.11 | 0.03 | 0.21 |
| Capex / Sales | 22.05% | 2.37% | 0.64% | 2.25% | 0.09% | 0.57% |
| Announcement Date | 3/16/18 | 3/12/19 | 3/12/20 | 3/11/21 | 3/29/22 | 4/17/23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +9,900.00% | 323 | |
| +8.96% | 105B | |
| -1.43% | 104B | |
| +4.40% | 22.94B | |
| -12.15% | 22.34B | |
| -4.36% | 19.25B | |
| -39.98% | 17.08B | |
| -10.04% | 16.96B | |
| +38.61% | 12.63B | |
| +313.59% | 8.49B |
- Stock Market
- Equities
- NBRVF Stock
- Financials Nabriva Therapeutics plc
